5 Key Takeaways

• 1

  Pegcetacoplan treatment for geographic atrophy showed progressive tissue preservation over 5 years in patients with age-related macular degeneration.

• 2

  In the GALE extension trial, pegcetacoplan reduced GA lesion growth by 24% overall, with higher reductions observed in nonsubfoveal patients.

• 3

  Patients treated continuously for 5 years preserved 3.9 mm² of retinal tissue, while those who crossed over from sham preserved only 1.9 mm².

• 4

  Early initiation of pegcetacoplan treatment resulted in approximately one and a half years of disease progression saved for patients.

• 5

  The safety profile of pegcetacoplan remained consistent, with low rates of adverse events such as infectious endophthalmitis and intraocular inflammation.